Tower Research Capital LLC (Trc) Tricida, Inc. Transaction History

Tower Research Capital LLC (Trc)

$3.68 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	SELL	$0.0 - $0.18 $0 - $5,288	-29,379 Reduced 99.68%	94 $0
Q4 2022 Feb 10, 2023	BUY	$0.14 - $12.49 $3,729 - $332,758	26,642 Added 941.08%	29,473 $4,000
Q3 2022 Nov 10, 2022	BUY	$8.51 - $13.6 $1,276 - $2,040	150 Added 5.59%	2,831 $29,000
Q2 2022 Aug 15, 2022	SELL	$7.31 - $11.85 $187,450 - $303,869	-25,643 Reduced 90.53%	2,681 $26,000
Q1 2022 May 12, 2022	BUY	$7.35 - $10.63 $192,974 - $279,090	26,255 Added 1268.97%	28,324 $233,000
Q4 2021 Feb 14, 2022	SELL	$4.19 - $9.56 $1,009 - $2,303	-241 Reduced 10.43%	2,069 $20,000
Q3 2021 Nov 15, 2021	SELL	$3.56 - $4.64 $1,003 - $1,308	-282 Reduced 10.88%	2,310 $10,000
Q2 2021 Aug 16, 2021	SELL	$3.95 - $5.41 $1,497 - $2,050	-379 Reduced 12.76%	2,592 $11,000
Q1 2021 May 17, 2021	SELL	$4.52 - $7.8 $44,738 - $77,204	-9,898 Reduced 76.91%	2,971 $16,000
Q4 2020 Feb 16, 2021	SELL	$4.37 - $9.46 $19,887 - $43,052	-4,551 Reduced 26.13%	12,869 $91,000
Q3 2020 Nov 16, 2020	BUY	$8.56 - $26.93 $128,151 - $403,169	14,971 Added 611.31%	17,420 $158,000
Q2 2020 Aug 13, 2020	BUY	$21.21 - $31.55 $44,350 - $65,971	2,091 Added 584.08%	2,449 $67,000
Q1 2020 May 15, 2020	BUY	$18.43 - $38.04 $6,597 - $13,618	358 New	358 $8,000
Q4 2019 Feb 07, 2020	SELL	$29.6 - $43.71 $54,878 - $81,038	-1,854 Closed	0 $0
Q3 2019 Nov 05, 2019	BUY	$29.87 - $42.22 $55,378 - $78,275	1,854 New	1,854 $57,000
Q2 2019 Aug 13, 2019	SELL	$31.16 - $39.46 $31,191 - $39,499	-1,001 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$19.96 - $38.62 $12,155 - $23,519	-609 Reduced 37.83%	1,001 $39,000
Q4 2018 Feb 14, 2019	BUY	$23.57 - $32.33 $37,947 - $52,051	1,610 New	1,610 $38,000

Others Institutions Holding TCDA

# of Institutions

Shares Held

30K

Call Options Held

124K

Put Options Held

46.5K

View Full List

About Tricida, Inc.

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

More about TCDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account